Mechlorethamine hydrochloride gel is filed at FDA for Mycosis Fungoides

Yaupon Therapeutics has filed at the FDA an application (NDA) for its gel formulation of mechlorethamine hydrochloride as a topical treatment for early-stage mycosis fungoides, the most common type of cutaneous T-Cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma. Mycosis fungoides is the most common type of Cutaneous T-Cell Lymphoma, a rare form of non-Hodgkin's lymphoma. The cause of mycosis fungoides remains unknown and there is no known cure. Unlike most non-Hodgkin's lymphomas, mycosis fungoides is caused by a mutation of T-cells. The malignant T-cells in the body initially migrate to the skin, causing various lesions to appear. These lesions typically begin as what appears to be a rash and may progress to form plaques and disfiguring tumors.